What Will Happen to ZELDA THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:ZLDAF) Next? The Stock Has Increase in Shorts

June 16, 2018 - By Ellis Scott

The stock of ZELDA THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:ZLDAF) registered an increase of 3.3% in short interest. ZLDAF’s total short interest was 9,400 shares in June as published by FINRA. Its up 3.3% from 9,100 shares, reported previously.

It closed at $0.09 lastly. It is down 0.00% since June 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid formulations for the treatment of various medical conditions in Australia. The company has market cap of $70.67 million. The firm is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. It currently has negative earnings. It has strategic alliances with Knop Laboratories and CannPal Pty Ltd; and partnerships with AusCann Limited and Aunt Zelda??s Inc, as well as the Complutens?? University, the Curtin University, and the Telethon Kids Institute.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: